Interleukins involved in Inflammatory Bowel Disease as new therapeutic targets

Current Immunology Reviews

Volumn 9, Issue 2, 2013, Pages 86-92

  Fonseca Camarillo, Gabriela ^a,b   Yamamoto Furusho, Jesús K ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Crohn's disease; Gene expression; Immunity; Inflammation; Inflammatory bowel diseases; Interleukins; Ulcerative colitis

Indexed keywords

BASILIXIMAB; CYTOKINE; CYTOKINE RECEPTOR; FONTOLIZUMAB; GAMMA INTERFERON; INFLAMMASOME; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; SECUKINUMAB; STAT PROTEIN; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ADAPTIVE IMMUNITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CROHN DISEASE; CYTOKINE RELEASE; ENTERITIS; GENE EXPRESSION; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; KERATINOCYTE; KUPFFER CELL; MACROPHAGE; MONOCYTE; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; T LYMPHOCYTE; TH17 CELL; ULCERATIVE COLITIS;

EID: 84891784208     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/1573395511309020003     Document Type: Article

References (74)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
2. Gologan S, Iacob R, Iancu D, et al. Inflammatory gene expression profiles in Crohn's disease and ulcerative colitis: A comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol. J Crohn Colitis. 2013; 7(8): 622-30.
3. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006; 3(7): 390-407.
4. Matsuda R, Koide T, Tokoro C, et al. Quantitive Cytokine mRNA Expression Profiles in the Colonic Mucosa of Patients with Steroid Naive Ulcerative Colitis during Active and Quiescent Disease. Inflamm Bowel Dis 2009; 15: 328-34.
5. Perše M, Cerar A. Dextran Sodium Sulphate Colitis Mouse Model: Traps and Tricks, J Biomed Biotechnol 2012; 718617. doi: 10.1155/2012/718617.
6. Fuss IJ. Is the Th1/Th2 paradigm of immune regulation applicable to IBD? Inflamm Bowel Dis 2008; 14 Suppl 2: S110-2.
7. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34
8. Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14(27): 4280-8.
9. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-6.
10. Sarra M, Pallone F, MacDonald T, Monteleone G. IL-23/IL-17 Axis in IBD Inflamm Bowel Dis 2010; 16: 1808-13
11. Kamada N, Hisamatsu T, Honda H, et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010; 16 (4): 568-75.
12. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-79.
13. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135: 1130-41.
14. Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006; 12: 558-65.
15. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38.
16. Lebel-Binay S, Berger A, Zinzindohoue F, Cugnenc P, Thiounn N, Fridman WH, Pages F. Interleukin-18: biological properties and clinical implications. Eur Cytokine Netw 2000; 11: 15-26
17. Siegmund B. Interleukin-18 in intestinal inflammation: friend and foe? Immunity 2010; 32: 300-2.
18. Zaki H, Lamkanfi M, Kanneganti T. The Nlrp3 inflammasome in IBD and colorectal tumorigenesis. Trends Immunol 2011; 32(4): 171-9.
19. Leach ST, Messina I, Lemberg DA, et al. Local and systemic interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 68-74.
20. Villeda-Ramírez MA, Mendivil-Rangel EJ, Domínguez-López A, Yamamoto-Furusho JK. Interleukin-18 upregulation is associated with the use of steroids in patients with ulcerative colitis. Inflamm Bowel Dis 2011; 17: E50-E51.
21. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1419-23.
22. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 2005; 128: 687-94.
23. Festen EA, Goyette P, Scott R, et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58: 799-804.
24. Marquez A, Orozco G, Marti{dotless}nez A, et al. Novel association of the interleukin 2-interleukin 21 region with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 1968-75.
25. Liu Z, Yang L, Cui Y, et al. IL-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1133-44.
26. Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, Sánchez-Muñoz F, Barreto-Zuñiga R, Dominguez-Lopez A. Interleukin 21 expression is increased in rectal biopsies from patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1090.
27. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004; 61: 567-79.
28. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
29. Hovhannisyan Z, Treatman J, Littman DR, et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011; 140: 957-65.
30. Hundorfean G, Neurath MF, Mudter J. Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18 (1): 180-6.
31. Fonseca-Camarillo G, Mendivil-Rangel E, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis. Inflamm Bowel Dis 2011; 17: E135-6.
32. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF-alpha. Immunity 2005; 22: 131-42.
33. Shioya M, Nishida Y, Ogawa Y, et al. Epithelial overexpression of interleukin-32a in inflammatory bowel disease. Clin Exp Immunol 2007; 149: 480-6
34. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121: 1108-11.
35. Caudell EG, Mumm JB, Poindexter N, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002; 168: 6041-6046.
36. Kunz S, Wolk K, Witte E, et al. Interleukin IL-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006; 15: 991-1004.
37. Andoh A, Shioya M, Nishida A, et al. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol 2009; 183: 687-95.
38. Camarillo GF, Furuzawa-Carballeda J, Martínez-Benítez B, Barreto-Zúñiga R, Yamamoto-Furusho JK. Role of the interleukin 24 in patients with ulcerative colitis. Inflamm Bowel Dis 2011; 17: 2209-10.
39. Knappe A, Hor S, Wittmann S, Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol 2000; 74: 3881-7.
40. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168: 5397-402
41. Dambacher J, Beigel F, Zitzmann K. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 2009; 58(9): 1207-17 3.
42. Gallagher G. Interleukin-19: multiple roles in immune regulation and disease. Cytokine Growth Factor Rev 2010; 21: 345-52.
43. Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets 2011; 15: 119-26.
44. Gallagher G, Dickensheets H, Eskdale J, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1: 442-50.
45. Liao YC, Liang WG, Chen FW, et al. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNFalpha. J Immunol 2002; 169: 4288-97.
46. Parrish-Novak J, Xu W, Brender T, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277: 47517-23.
47. Wolk K, Witte E, Warszawska K, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39: 3570-81.
48. Fickenscher H et al. The interleukin-10 family of cytokines. Trends Immunol 2002; 23(2): 89-96.
49. Azuma YT, Matsuo Y, Kuwamura M, et al. Interleukin-19 Protects Mice from Innate-mediated Colonic Inflammation. Inflamm Bowel Dis 2010; 16: 1017-28.
50. Yamamoto-Furusho JK, Álvarez-León E, Fragoso JM, Gozalishvilli A, Vallejo M, Vargas-Alarcón G. Protective role of interleukin-19 gene polymorphisms in patients with ulcerative colitis. Hum Immunol 2011; 72 (11): 1029-32.
51. Zenewicz LA, Yancopoulos GD, Valenzuela DM, et al. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008; 29: 947-57.
52. Sugimoto K, Ogawa A, Mizoguchi E, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008; 118: 534-44.
53. Andoh A, Zhang Z, Inatomi O, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005; 129: 969-84.
54. Yamamoto-Furusho JK, Miranda-Pérez E, Fonseca-Camarillo G, Sánchez-Muñoz F, Dominguez-Lopez A, Barreto-Zuñiga R. Colonic epithelial upregulation of interleukin 22 (IL-22) in patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1823.
55. Blumberg H, Conklin D, Xu WF, et al. Interleukin-20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104: 9-19.
56. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 15; 178(4): 2229-40.
57. Kragstrup TW, Otkjaer K, Holm C, et al. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine 2008; 41(1): 16-23.
58. Chen WY, Cheng BC, Jiang MJ, et al. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26(9): 2090-5.
59. Li HH, Cheng HH, Sun KH, et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol 2008; 129(2): 277-85.
60. Hsu YH, Chang MS. Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum 2010; 62(11): 3311-21.
61. Rich BE, Kupper TS. Cytokines: IL-20-a new effector in skin inflammation. Curr Biol 2001; 11: R531-R534.
62. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83: 1181-93.
63. Fonseca-Camarillo G, Furuzawa-Carballeda J, Llorente L, Yamamoto-Furusho JK. IL-10-and IL-20 Expressing Epithelial and Inflammatory Cells are increased in Patients with Ulcerative Colitis. J Clin Immunol 2013; 33: 640-8.
64. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006; 55: 1131-7.
65. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351: 2069-79.
66. Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM. Basiliximab for the treatment of steroidresistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 2006; 23: 1435-42.
67. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-96.
68. Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006; 101: 793-7.
69. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367(16): 1519-28.
70. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012; 367(7): 616-24.
71. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebocontrolled trial. Gut 2012; 61: 1693-700.
72. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32.
73. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699-710.
74. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369: 711-21.